Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

BACKGROUND: Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Khor, Sara, Beca, Jaclyn, Krahn, Murray, Hodgson, David, Lee, Linda, Crump, Michael, Bremner, Karen E, Luo, Jin, Mamdani, Muhammad, Bell, Chaim M, Sawka, Carol, Gavura, Scott, Sullivan, Terrence, Trudeau, Maureen, Peacock, Stuart, Hoch, Jeffrey S
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148552/
https://ncbi.nlm.nih.gov/pubmed/25117912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-586
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars